Search research articles
Contact Us
Filters
Showing results (31-40 of 263) with videos related to
Page
of 27
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
October 3, 2015
Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy
Elizabeth A Guancial, Jonathan E Rosenberg, Christopher J Sweeney
The New England Journal of Medicine
|
October 10, 2019
Enzalutamide in Metastatic Prostate Cancer. Reply
Ian D Davis, Martin R Stockler, Christopher J Sweeney
Integrated Environmental Assessment and Management
|
April 4, 2026
Dose response OECD 216 studies for agrochemicals
Christopher J Sweeney, Melanie Bottoms, Kerry Hutcheson, et al.
European Urology Focus
|
July 21, 2017
Delivering Optimal Care for Metastatic Prostate Cancer: A Strengthening Alliance Between Urologists and Medical Oncologists
Alberto Briganti, Maria De Santis, Gianluca Giannarini, et al.
Environmental Toxicology and Chemistry
|
February 23, 2025
Functional versus compositional tests in the risk assessment of the impacts of pesticides on the soil microbiome
Christopher J Sweeney, Melanie Bottoms, Rishabh Kaushik, et al.
Nature Reviews. Clinical Oncology
|
November 27, 2025
Personalized intensification of treatment for hormone-sensitive prostate cancer
Michael A Cilento, Lisa M Butler, Louise Emmett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2019
What Does Metastasis-Free Survival Actually Mean?
Christopher J Sweeney, Richard De Abreu Lourenco, Anis A Hamid, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
June 2, 2016
Approach to Oligometastatic Prostate Cancer
Brandon Bernard, Boris Gershman, R Jeffrey Karnes, et al.
Cancer
|
November 27, 2019
Impact of age at diagnosis of de novo metastatic prostate cancer on survival
Brandon Bernard, Colin Burnett, Christopher J Sweeney, et al.
Clinical Genitourinary Cancer
|
October 16, 2013
Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event
Noah M Hahn, Constantin T Yiannoutsos, Kristina Kirkpatrick, et al.
Page
of 27
Search research articles
Search
Showing results (31-40 of 263) with videos related to
Sort By:
Page
of 27
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
October 3, 2015
Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy
Elizabeth A Guancial, Jonathan E Rosenberg, Christopher J Sweeney
The New England Journal of Medicine
|
October 10, 2019
Enzalutamide in Metastatic Prostate Cancer. Reply
Ian D Davis, Martin R Stockler, Christopher J Sweeney
Integrated Environmental Assessment and Management
|
April 4, 2026
Dose response OECD 216 studies for agrochemicals
Christopher J Sweeney, Melanie Bottoms, Kerry Hutcheson, et al.
European Urology Focus
|
July 21, 2017
Delivering Optimal Care for Metastatic Prostate Cancer: A Strengthening Alliance Between Urologists and Medical Oncologists
Alberto Briganti, Maria De Santis, Gianluca Giannarini, et al.
Environmental Toxicology and Chemistry
|
February 23, 2025
Functional versus compositional tests in the risk assessment of the impacts of pesticides on the soil microbiome
Christopher J Sweeney, Melanie Bottoms, Rishabh Kaushik, et al.
Nature Reviews. Clinical Oncology
|
November 27, 2025
Personalized intensification of treatment for hormone-sensitive prostate cancer
Michael A Cilento, Lisa M Butler, Louise Emmett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2019
What Does Metastasis-Free Survival Actually Mean?
Christopher J Sweeney, Richard De Abreu Lourenco, Anis A Hamid, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
June 2, 2016
Approach to Oligometastatic Prostate Cancer
Brandon Bernard, Boris Gershman, R Jeffrey Karnes, et al.
Cancer
|
November 27, 2019
Impact of age at diagnosis of de novo metastatic prostate cancer on survival
Brandon Bernard, Colin Burnett, Christopher J Sweeney, et al.
Clinical Genitourinary Cancer
|
October 16, 2013
Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event
Noah M Hahn, Constantin T Yiannoutsos, Kristina Kirkpatrick, et al.
Page
of 27